David Schlanger's holdings primarily consist of equity in Progyny, where he has vested significant stock options and restricted shares. In 2022 alone, he was granted 333,000 stock options and 84,000 restricted stock units. As of his transition to Executive Chairman,...

David Schlanger's holdings primarily consist of equity in Progyny, where he has vested significant stock options and restricted shares. In 2022 alone, he was granted 333,000 stock options and 84,000 restricted stock units. As of his transition to Executive Chairman, he had considerable wealth tied up in these shares, particularly when Progyny's stock performance surged. The decisions around his equity grants reflect Progyny’s performance goals. Despite his previous substantial compensation as CEO, which peaked around $862,462 in 2021, his stake in the company remains a driving factor for his financial success and aligns his interests with that of shareholders. Schlanger's wealth in his holdings significantly fluctuated during his tenure, highlighting the link between his leadership outcomes and stock market movements.